Cargando…
Add-on Pyridostigmine Enhances CD4(+) T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study
BACKGROUND: In human immunodeficiency virus (HIV)-infection, persistent T-cell activation leads to rapid turnover and increased cell death, leading to immune exhaustion and increased susceptibility to opportunistic infections. Stimulation of the vagus nerve increases acetylcholine (ACh) release and...
Autores principales: | Valdés-Ferrer, Sergio I., Crispín, José C., Belaunzarán-Zamudio, Pablo F., Rodríguez-Osorio, Carlos A., Cacho-Díaz, Bernardo, Alcocer-Varela, Jorge, Cantú-Brito, Carlos, Sierra-Madero, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651246/ https://www.ncbi.nlm.nih.gov/pubmed/29093707 http://dx.doi.org/10.3389/fimmu.2017.01301 |
Ejemplares similares
-
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol
por: Fragoso-Saavedra, Sergio, et al.
Publicado: (2020) -
Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial
por: Fragoso-Saavedra, Sergio, et al.
Publicado: (2022) -
Recognition of Brain Metastases Using Gadolinium-Enhanced SWI MRI: Proof-of-Concept Study
por: Ceballos-Ceballos, Joel, et al.
Publicado: (2020) -
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial
por: Belaunzarán-Zamudio, Pablo F., et al.
Publicado: (2017) -
Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation
por: Soufi-Afshar, Iman, et al.
Publicado: (2016)